Results for tag: "Progressive Supranuclear Palsy Drug"

Progressive Supranuclear Palsy (PSP) is a rare neurological disorder that affects movement, balance, and eye movements. It is a degenerative disorder that affects the brainstem and basal ganglia, leading to a wide range of symptoms. Treatment for PSP is limited, and there are currently no drugs approved specifically for the disorder. However, there are a number of drugs used to treat the symptoms of PSP, which are classified as Central Nervous System (CNS) drugs. These drugs are used to treat the motor symptoms of PSP, such as difficulty walking, and the cognitive symptoms, such as memory loss. The PSP drug market is a small but growing segment of the CNS drug market. It is a niche market, with a limited number of drugs available. These drugs are typically used in combination with other treatments, such as physical therapy and occupational therapy. Companies in the PSP drug market include AbbVie, Biogen, and Merck. Show Less Read more